HubSpot Inc vs Oruka Therapeutics Inc. Common Stock — how do they compare? HubSpot Inc trades at $227.11 (market cap $11.28B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B). The key difference: HubSpot Inc is far larger — about 2.2× Oruka Therapeutics Inc. Common Stock's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| HUBS | ORKA | |
|---|---|---|
Market Cap | $11.28B | $5.08B |
Volume | 1,027,877.02 | 685,276 |
Sector | Technology | Health |
52-Week High | $494.58 | $113.08 |
52-Week Low | $170.39 | $26.19 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $10.18B | $4.21B |
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $221.02, down 1.05% on the day, with a neutral technical signal. The company shows strong revenue growth, reaching $3.13B in 2025, and has beaten earnings estimates for three consecutive quarters. Recent news highlights its AI strategy and partnership with OpenAI, aiming to boost margins. Cash flow from operations is robust at $760.72M, though valuation ratios like a P/E of 80.51 remain elevated.
The outlook is cautiously optimistic, with a consensus price target of $244.09 implying upside potential. Key opportunities include AI-driven growth and margin expansion, but risks involve high valuation, competitive pressures, and sensitivity to economic cycles. Analyst sentiment is predominantly buy-rated, supporting a positive medium-term view.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →